The document explains some regulatory flexibilities that can be applied to help pharmaceutical companies cope with the consequences of the pandemic, while ensuring a high level of quality, safety and efficacy for medicinal products made available to patients in the EU.
EU Member States, supported by the Commission, adopted an EU toolbox to use mobile applications for efficient contact tracing and warning in response to the coronavirus pandemic.
Large-scale testing helps detect and slow down the COVID19 pandemic, paving the way for a gradual return to our normal lives. The new guidelines are crucial for the European Roadmap towards lifting coronavirus containment measures.
The Guidance document aims to facilitate a common approach across EU Member States to the donation, collection, testing, processing, storage, distribution and monitoring of convalescent plasma for the treatment of Covid-19 patients.
To support and encourage cross-border healthcare cooperation between national, regional and local authorities, the Commission has today issued practical guidance to Member States.
This postponement will take the pressure off national authorities, notified bodies, manufacturers and other actors so they can focus fully on urgent priorities related to the coronavirus crisis.
During the webinar organised by the EU Health Policy Platform, the ECDC will present an epidemiological situation and risk assessment of COVID-19, the Commission will give an overview on how it is supporting the Member States, NGOs will present the protection of the elderly and other groups at risk, and there will be a virtual roundtable on NGOs’ and stakeholders’ concerns and suggested best practices.
Based on the experience with the European Reference Networks, the initiative will help to create rapid connections across Europe among the hospitals indicated by the Member States as reference centres for COVID-19.
Check the EU’s response and ECDC’s assessment.
The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new, harmonised recommendations for sponsors on how to manage clinical trials to mitigate the negative effects of the COVID-19 pandemic.